A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
← catalyst calendarNCT07180355 · readout in 580 d
Sponsored by Solid Biosciences Inc. (industry) · SLDB — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
10estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-22 | actual | When the study began enrolling |
| Primary completion | 2028-03-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-02-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Friedreich's Ataxia (FA)
Intervention
- Drug: SGT-212
Primary outcome
what the primary-completion date above is the date OFIncidence and Severity of Treatment Emergent Adverse Events (TEAEs)
measured Month 12
Permalink · SLDB's whole pipeline · Catalyst calendar · Every registered study · What changed